1. Home
  2. SNBR vs MOLN Comparison

SNBR vs MOLN Comparison

Compare SNBR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sleep Number Corporation

SNBR

Sleep Number Corporation

N/A

Current Price

$4.59

Market Cap

188.2M

ML Signal

N/A

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.86

Market Cap

158.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SNBR
MOLN
Founded
1987
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
188.2M
158.9M
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
SNBR
MOLN
Price
$4.59
$4.86
Analyst Decision
Hold
Buy
Analyst Count
3
2
Target Price
$10.00
$8.38
AVG Volume (30 Days)
683.0K
1.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,682,296,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$285.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$3.36
52 Week High
$13.94
$5.36

Technical Indicators

Market Signals
Indicator
SNBR
MOLN
Relative Strength Index (RSI) 24.51 54.87
Support Level $3.73 $3.50
Resistance Level $8.94 $5.36
Average True Range (ATR) 0.67 0.18
MACD -0.26 -0.03
Stochastic Oscillator 0.31 38.04

Price Performance

Historical Comparison
SNBR
MOLN

About SNBR Sleep Number Corporation

Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: